Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background. Biological agents used to treat moderate-to-severe plaque psoriasis have been associated with Candida infection and other serious infections. It is, however, necessary to verify whether biologic agents increase the risk of Candida infection and serious infections and whether these risks...
Saved in:
Main Authors: | Yue Feng, Baosen Zhou, Zhen Wang, Guijuan Xu, Lili Wang, Tingting Zhang, Yanping Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | International Journal of Clinical Practice |
Online Access: | http://dx.doi.org/10.1155/2022/2442603 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Breakthrough Psoriasis in Patients Receiving Biologicals
by: Damsin T, et al.
Published: (2025-01-01) -
Mixed Fungal Infection (Aspergillus, Mucor, and Candida) of Severe Hand Injury
by: Milana Obradovic-Tomasev, et al.
Published: (2014-01-01) -
A ‘Serious’ Bloodstream Infection in an Infant
by: Shauna Flavelle, et al.
Published: (2007-01-01) -
Cross-sectional study of proteomic differences between moderate and severe psoriasis
by: Lingling Wu, et al.
Published: (2025-01-01) -
Meta-analysis of the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis
by: Yanxia Cai, et al.
Published: (2025-01-01)